From left, Christine Peters, Esq., Dragos Banu, MD, Sarah Harm, MD, MS, and Heidi Melbostad, PhD Vermont Business Magazine Four members of the communities served by the University of Vermont Health ...

Naomi Ackerman; Rajinder Atwal, MD; Marva Bailer; Jess Bailey; Dawn Belamarich; Sarah Bencie; Gogo Bethke; Dedorah Brown; April Callis-Birchmeier, CSP, PMP®, CCMPtm; Jaymee Chan; Heidi Clarke ... 20 ...

Kennedy and Merck: Robert F. Kennedy Jr., Mr. Trump ... how many actions they’re taking right out of the gate,” said Heidi Altman, the federal director of advocacy at the National Immigration ...

A woman's hands star in a Lilly spot, shown playing key role in activities like gardening -- and discovering a lump in her ...

The 2025 tax season officially opened Jan. 27, when the IRS and the Vermont Department of Taxes will begin accepting personal income tax returns for tax year 2024. The 2025 filing deadline for ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

Merck reported Q4 sales of $15.62 billion, up 7% YoY, exceeding the $15.49 billion estimate. Goldman Sachs raises Merck's price target to $135, citing growth potential. NOW OPEN: 200 Charter ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

Merck (NSE:PROR) posted adjusted earnings per share (EPS) of $1.72 for Q4, missing the analyst consensus of $1.81 by $0.09. However, revenue for the quarter came in at $15.6 billion, beating the ...

Merck stock (NYSE: MRK) lost about 10% in 2024, underperforming the broader S&P 500 index, which gained 23% for the year. Despite strong performances from other pharmaceutical giants like Eli ...

For the recently completed fourth quarter, Merck booked an adjusted profit of $1.72 per share on $15.6 billion in revenue. Sales of top-selling cancer treatment Keytruda climbed 19% to $7.84 billion.